News | Cath Lab | September 03, 2019

FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy

Agency’s Breakthrough Device Designation program allows for priority review of coronary calcium modification technology

FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy

September 3, 2019 — Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Shockwave intravascular lithotripsy (IVL) system with the Shockwave C2 Coronary IVL Catheter. The device is currently the subject of an Investigational Device Exemption (IDE) study called DISRUPT CAD III. The Shockwave C2 IVL Catheter is a proprietary tool designed to fracture problematic calcium using sonic pressure waves in order to facilitate stent delivery, deployment and optimal expansion, thereby improving blood flow to the heart muscle.

The FDA Breakthrough Device Program is intended to help patients and healthcare providers receive more timely access to medical devices that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA will provide Shockwave Medical with priority review and interactive communication during the Shockwave C2 IVL Catheter premarket review phase.

Coronary artery calcium physically impairs blood flow and restricts artery dilation, which inhibits stent expansion1 and is perhaps the single most important predictor of restenosis and early stent thrombosis,2 or coronary artery re-narrowing and blood clots, within the stent after-stent procedures.

DISRUPT CAD III is a prospective, non-randomized, multicenter global IDE study to demonstrate the safety and effectiveness of the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter in de novo, calcified, stenotic, coronary arteries prior to stenting. The study is approved to enroll 442 patients at 50 centers in the United States and Europe, and is led by co-principal investigators Dean Kereiakes, M.D., and Jonathan Hill, M.D. As reported in the company’s second quarter earnings call, the study had enrolled 108 patients as of June 30, 2019.

Shockwave C2 Coronary IVL catheters are commercially available for the treatment of de novo coronary artery disease in Europe and select other geographies; they are limited to investigational use in the United States.

For more information: www.shockwavemedical.com

 

Related Vascular Lithotripsy Content:

FDA Clears Coronary Intravascular Lithotripsy to Breakup Calcified Lesions With Sound Waves — Feb. 2021

VIDEO: Breaking Up Calcified Lesions Without Vessel Trauma

Intravascular Lithotripsy: Will This New Investigational Technology Crack Calcium’s Code in the U.S.?

FDA Clears Lithoplasty Balloon That Shatters Calcified Lesions With Ultrasound

 

References

1. Chambers J.W., Feldman R.L., Himmelstein S.I., et al.Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). Journal of the American College of Cardiology: Cardiovascular Interventions, May 2014. doi: 10.1016/j.jcin.2014.01.158.

2. Généreux P., Madhavan M.V., Mintz G.S., et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. Journal of the American College of Cardiology, May 2014. doi: 10.1016/j.jacc.2014.01.034. Epub 2014 Feb 19.

Related Content

Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav

SpectraWave is developing a a new intravascular imaging system that combines two currently available modalities. This likely includes optical coherence tomography (OCT), left, which can define structures within the vessel and vessel wall.  Near infrared spectroscopy (NIRS), right, enables a spectral chemical analysis of the vessel walls to show areas of high lipid content, and specifically can identify lipid-core plaques that are associated with heart attack-causing plaque ruptures.

News | Cath Lab | February 16, 2021
February 16, 2021 – SpectraWave Inc.
Videos | Cath Lab | February 04, 2021
Cindy Grines, M.D., MSCAI, FACC, president
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar